![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Edarbi-Generic (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) small molecule drug, which is indicated for the treatment of hypertension.
Lead Product(s): Azilsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Edarbi-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 04, 2024
Details:
Through the acquisition, Hasten will own the Marketing Authorisation Holder rights of products in 8 countries, which includes Edarbi (azilsartan medoxomil) indicated for the treatment of hypertension.
Lead Product(s): Azilsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Edarbi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hasten Biopharmaceutic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 02, 2024
Details:
Edarbyclor-Generic is an angiotensin II receptor blocker (ARB) and a thiazide like diuretic combination product indicated for the treatment of hypertension.
Lead Product(s): Azilsartan,Chlorthalidone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Edarbyclor-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2024
Details:
The proceeds will fund the future acquisitions and business development of five cardiovascular and metabolic products, including Ebrantil®, Edarbi®, Blopress®, Basen®, and Actos®. Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker, used to treat hypertension.
Lead Product(s): Azilsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Edarbi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: CBC Group
Deal Size: $315.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 20, 2023
Details:
Under the acquisition agreement, Hasten Biopharma will have exclusive rights to five drugs including, Ebrantil (urapidil), Edarbi (azilsartan medoxomil), Blopress (candesartan cilexetil), Basen®, and Actos® in mainland China.
Lead Product(s): Azilsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Edarbi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hasten Biopharmaceutic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 31, 2022
Details:
Lupin received tentative Abbreviated New Drug Application (ANDA) approval of Azilsartan Medoxomil Tablets, an angiotensin II receptor antagonist, which is a generic version of Edarbi® Tablets of Arbor Pharmaceuticals, used in the treatment of hypertension.
Lead Product(s): Azilsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Azilsartan Medoxomil-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 24, 2021